BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week

Traders Union
All News
Business & Wealth
Companies
BioAge Labs, Inc. explores new drugs

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

15.05.2026

BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week — BioAge Labs, Inc. explores new drugs

BioAge Labs, Inc. CEO Kristin Fortney participated in a panel at Fierce Biotech Week Boston with R&D leaders from Amgen, Novo Nordisk, and Wave Life Sciences to examine the next frontier of obesity and cardiometabolic drug development beyond incretin therapies.

The panel explored strategies for addressing metabolic diseases with emerging mechanisms and highlighted the role of industry collaboration in accelerating clinical progress. Insights from the discussion underscore renewed momentum among biotech firms seeking alternatives to current obesity drug classes.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

BioAge Labs has reported Phase 1 trial data showing that its 60 mg BGE-102 dose matches the efficacy of 120 mg in reducing hsCRP levels, according to company findings. The results highlight BioAge’s continued focus on cardiometabolic research. The company’s R&D efforts remain in line with broader industry discussions on obesity and metabolic disease therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Adobe and AI: Is the creative software giant losing its edge?

By Dmytro Kharkov
1 hour ago

Adobe and AI: Is the creative software giant losing its edge?

Editors' Picks

Solana vs. Base: Who will dominate the token launch market?

By Pavlo Kot
Yesterday

Solana vs. Base: Who will dominate the token launch market?

Editors' Picks

Jobs in crypto: Which specialists are in demand now?

By Pavlo Kot
17.10.2026

Jobs in crypto: Which specialists are in demand now?

Editors' Picks

All Editors' Top Picks

Latest BioAge Labs News

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery

By Igor Krasulya
15.10.2026

DeepOriginBio partnership accelerates BioAge Labs progress on human aging drug discovery

Companies

BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice

By Mykhailo Ihnatenko
28.09.2026

BioAge Labs presents oral NLRP3 inhibition research on reversing aging effects in mice

Companies

Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research

By Andreas Kristo
30.07.2026

Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research

Companies

All BioAge Labs News

Dmytro Kharkov
1 hour ago

Adobe and AI: Is the creative software giant losing its edge?

Pavlo Kot
Yesterday

Solana vs. Base: Who will dominate the token launch market?

Pavlo Kot
17.10.2026

Jobs in crypto: Which specialists are in demand now?

Anastasiia Chabaniuk
16.10.2026

Poland's crypto paradox: A growing market caught in regulatory deadlock

Eugene Komchuk
16.10.2026

Jimmy Song: Trump has failed to meet Bitcoiners' expectations

Daria Chernytska
10 min ago

Jim Cramer: Surprised EU is not shutting down China amid $1.2 trillion surplus

Yaroslav Dmytrenko
1 hour ago

WTI refining margins fall sharply to $55 a barrel, Javier Blas notes

Eugene Komchuk
1 hour ago

Robert Peston: UK creditors and investors may be too harsh, he says

Daria Chernytska
3 hours ago

Sumit Gupta: India collected ₹1,096 crore in crypto TDS from FY22-23 to FY24-25

Alena Volkova
3 hours ago

Anyone with over €30,000 in assets faces 36 percent tax, Jeroen Blokland notes

Top News

Ivan Andriyenko
1 hour ago

Gold rises above $4,180 as investors reassess Fed policy outlook

Gold rises above $4,180 as investors reassess Fed policy outlook

Dmytro Kharkov
1 hour ago

Adobe and AI: Is the creative software giant losing its edge?

Adobe and AI: Is the creative software giant losing its edge?

Andrey Mastykin
1 hour ago

CXMT shares drop 7% despite forecast profit turnaround

CXMT shares drop 7% despite forecast profit turnaround

Olga Shendetskaya
2 hours ago

Oil prices tumble as Russian export prospects outweigh Gulf shipping risks

Oil prices tumble as Russian export prospects outweigh Gulf shipping risks

Eugene Komchuk
3 hours ago

Qubic blockchain halts operations after $1.4 million crypto theft

Qubic blockchain halts operations after $1.4 million crypto theft

Top 5 companies for you

United States

Live News

Igor Krasulya
Now

French bond yields face pressure as unrest threatens budget plans

Mykhailo Ihnatenko
Now

Ethereum price prediction: Can ETH break $2,440 before another liquidation wave?

Eugene Komchuk
Now

Circle plans to expand USDC into 40 new markets

Hanna Syniavska
Now

Shell plans to sell French mobility assets to DCC Energ

Anton Kharitonov
Now

EUR/USD holds above 1.1260 as falling U.S. yields overshadow sticky inflation

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.